Performance of super 7 patent medicine enterprises anticipates new drugs supporting performance growth

January 2, 2014 source: the fundamentals of pharmaceutical listed companies in China Securities Journal in 2013 showed an overall positive trend As of December 31, a total of 55 pharmaceutical listed companies have issued 2013 performance forecast, of which 42 enterprises, accounting for 76.4%, are expected to increase performance, make profits and turn losses According to the analysis of industry insiders, the investment in new drug research and development in previous years is now entering the harvest period, driving the company's performance growth In addition, as the downstream of the industrial chain, the hospital business is expected to become a new driving force for growth According to statistical data, 55 pharmaceutical listed companies issued 2013 annual performance forecast as of December 31 Among them, there are 34 enterprises with increased performance in advance, 8 enterprises with decreased performance in advance, 3 enterprises with loss in advance, 6 enterprises with profit and 2 enterprises with loss turned Among the pre increased enterprises, there are six companies with a year-on-year growth rate of more than 100% in the pre announced net profit, namely, Beijing new pharmaceutical, Jiaying pharmaceutical, Duyiwei, Xinfu pharmaceutical, Asia Pacific pharmaceutical and Rhine bio Among them, Asia Pacific pharmaceutical and Rhine bio both turned losses in 2013 Asia Pacific pharmaceutical industry lost 25.71 million yuan in 2012, and is expected to achieve a net profit of 2-8 million yuan in 2013; Rhine bio industry lost 65.96 million yuan in 2012, and is expected to achieve a net profit of 30-35 million yuan in 2013 There are 23 companies with a year-on-year growth rate of 30% - 100% in the forecast net profit, including Yunnan Baiyao, Da'an gene, taiantang, Kelun pharmaceutical, etc Most of the growth of these companies is due to the growth of main business income Influenced by the rising price of raw materials, the increase of management cost and the adjustment of product sales structure, the net profit of Furui Co., Ltd and Harbin Pharmaceutical Co., Ltd decreased by more than 20% year-on-year The decline of Shanghai Laishi's net profit was mainly caused by the "natural disaster" From its listing in 2010 to 2012, the net profit increased year by year, but in 2013, the net profit decreased year by year The direct economic loss of the plant area affected by typhoon is estimated to be about 60 million yuan Among the loss making enterprises, * ST Jintai is currently in a state of no main business and is insolvent and unable to finance The major shareholders of the company have been working hard to resume listing On the evening of December 31, the company announced that Shenzhen Zhongnan United Industry Co., Ltd agreed to grant a full exemption to the remaining debts owed by * ST Jintai of 20.4 million yuan This debt relief may turn the company's performance into profit and realize shell protection As the VC price of the leading product of Northeast Pharmaceutical continues to be at a low level, it may lose 90-120 million yuan; as the company is in the transformation stage of "living on the new and tasting the gall", the management and financial expenses of Haixiang pharmaceutical will surge, and it may lose 35-50 million yuan Yunnan Baiyao, the "giant" in the pharmaceutical industry, has a spectacular performance scale in 2013 Yunnan Baiyao is expected to increase by 39% - 58%; the net profit is also increased to 220000-2500000000 yuan from 1582510000 yuan in the same period of 2012 It should be noted that, although the overall performance of pharmaceutical listed companies is rising well, most companies only continue the momentum of profit growth since the third quarter of this year, and few companies have achieved rapid performance development New drugs support performance growth among companies with performance growth, the sales volume of new products and featured drugs will undoubtedly become the driving force to boost their performance Since the listing of Shuanglu pharmaceutical in 2010, the growth rate of net profit has been keeping a "stride forward" pace In 2013, it is expected to achieve a net profit of 57721-72151 million yuan, an increase of about 50% year-on-year In 2012, the figure was 48.01 million yuan In recent years, Shuanglu pharmaceutical industry is based on the research and development of therapeutic specialty drugs The company's products beconone accounted for 50% of the sales revenue in 2012, while the second and third-line products have contributed half of the revenue, reaching 500 million yuan In 2013, temozolomide, a brain cancer treatment product of Shuanglu pharmaceutical, began to be sold on the market, and the contribution rate of second and third-line products will increase According to Liang Shujie, Secretary of the board of directors of Shuanglu Pharmaceutical Co., Ltd., the research and development of the company's two first heavy-duty drugs has made progress "The company has completed the clinical research of dasatinib and applied for production; the clinical trial of lenalidomide is progressing smoothly, and it is expected to apply for production in the first quarter of 2014." According to this calculation, the above two products may be listed in 2015 and contribute to profits Similar to the growth model of Shuanglu pharmaceutical industry, Kelun pharmaceutical, the "infusion leader", applied to the State Food and Drug Administration in July 2013 for two kinds of clinical trial drugs: acitinib and lapatinib p-toluenesulfonate, both of which are anti-tumor targeted drugs "There are 242 projects under research of the company, and the overall schedule for the listing of new drugs is: 11 varieties in 2014, 5 varieties in 2015, 15 varieties in 2016, 4 varieties in 2017, 4 varieties in 2018, and about 3 varieties in 2019." Wang Jingyi, President of Kelun Pharmaceutical Research Institute, said that the company's R & D expenses will account for about 6% of sales revenue in the next three years, compared with about 2% in previous years Industry insiders told China Securities News that at present, the demand of the pharmaceutical market is changing from antibiotics to specialty drugs, especially in the areas of cancer, cardiovascular and cerebrovascular diseases, blood and other serious diseases, which are also popular with listed companies, such as Hengrui pharmaceutical, Yibai pharmaceutical, Tianshili, Zhongheng group, and xinlitai In addition, a number of R & D giants, such as Jingxin pharmaceutical, Laimei pharmaceutical, Hengrui pharmaceutical and Fosun Pharmaceutical, are also expected to maintain their performance growth by virtue of the heavyweight new drugs they hold